Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones. The company was incorporated in 2021 and is based in Sydney, Australia.
Price analytics
Returns
1 day
13.0%
1 week
-7.1%
1 month
-31.6%
3 months
-54.4%
6 months
-33.3%
1 year
—
3 years
—
Risk
Volatility (1y ann.)
101.8%
Beta vs ASX 200
1.46
Sharpe (1y)
-0.31
VaR 95% (1-day)
-9.7%
Max drawdown (1y)
-65.2%
Off 1-year high
-60.6%
Technicals
RSI(14)
19
OS
vs 50DMA
-35.2%
vs 200DMA
-36.1%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value80.0
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
47
Price / Sales
—
Growth—
Revenue growth (1y)
—
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health69.2
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum2.2
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
10
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).